Comment

. 2018 Nov;29(6):e88.

doi: 10.3802/jgo.2018.29.e88.

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Koji Matsuo¹, Malcolm S Ross², Mayu Yunokawa³, Marian S Johnson⁴, Hiroko Machida⁵, Kohei Omatsu⁶, Merieme M Klobocista⁷, Dwight D Im⁸, Shinya Satoh⁹, Tsukasa Baba¹⁰, Yuji Ikeda¹¹, Stephen H Bush¹², Kosei Hasegawa¹³, Erin A Blake¹⁴, Munetaka Takekuma¹⁵, Masako Shida¹⁶, Masato Nishimura¹⁷, Sosuke Adachi¹⁸, Tanja Pejovic¹⁹, Satoshi Takeuchi²⁰, Takuhei Yokoyama²¹, Yutaka Ueda²², Keita Iwasaki²³, Takahito M Miyake²⁴, Shiori Yanai²⁵, Tadayoshi Nagano²⁶, Tadao Takano²⁷, Mian Mk Shahzad¹², Frederick R Ueland⁴, Joseph L Kelley², Lynda D Roman⁵

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. koji.matsuo@med.usc.edu.
² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee-Womens Hospital, University of Pittsburgh, Pittsburgh, PA, USA.
³ Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁴ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, KY, USA.
⁵ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
⁶ Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
⁷ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
⁸ The Gynecologic Oncology Center, Mercy Medical Center, Baltimore, MD, USA.
⁹ Department of Obstetrics and Gynecology, Tottori University, Tottori, Japan.
¹⁰ Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan.
¹¹ Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
¹² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
¹³ Department of Obstetrics and Gynecology, Saitama Medical University International Medical Center, Saitama, Japan.
¹⁴ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, Denver, CO, USA.
¹⁵ Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
¹⁶ Department of Obstetrics and Gynecology, Tokai University, Kanagawa, Japan.
¹⁷ Department of Obstetrics and Gynecology, Tokushima University, Tokushima, Japan.
¹⁸ Department of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
¹⁹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA.
²⁰ Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan.
²¹ Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka, Japan.
²² Department of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
²³ Department of Obstetrics and Gynecology, Aichi Medical University, Aichi, Japan.
²⁴ Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.
²⁵ Department of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama, Japan.
²⁶ Department of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.
²⁷ Department of Obstetrics and Gynecology, Tohoku University, Miyagi, Japan.

PMID: 30207096
PMCID: PMC6189428
DOI: 10.3802/jgo.2018.29.e88

Comment

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Koji Matsuo et al. J Gynecol Oncol. 2018 Nov.

. 2018 Nov;29(6):e88.

doi: 10.3802/jgo.2018.29.e88.

Authors

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. koji.matsuo@med.usc.edu.
² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee-Womens Hospital, University of Pittsburgh, Pittsburgh, PA, USA.
³ Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁴ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, KY, USA.
⁵ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
⁶ Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
⁷ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
⁸ The Gynecologic Oncology Center, Mercy Medical Center, Baltimore, MD, USA.
⁹ Department of Obstetrics and Gynecology, Tottori University, Tottori, Japan.
¹⁰ Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan.
¹¹ Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
¹² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
¹³ Department of Obstetrics and Gynecology, Saitama Medical University International Medical Center, Saitama, Japan.
¹⁴ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, Denver, CO, USA.
¹⁵ Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
¹⁶ Department of Obstetrics and Gynecology, Tokai University, Kanagawa, Japan.
¹⁷ Department of Obstetrics and Gynecology, Tokushima University, Tokushima, Japan.
¹⁸ Department of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
¹⁹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA.
²⁰ Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan.
²¹ Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka, Japan.
²² Department of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
²³ Department of Obstetrics and Gynecology, Aichi Medical University, Aichi, Japan.
²⁴ Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.
²⁵ Department of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama, Japan.
²⁶ Department of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.
²⁷ Department of Obstetrics and Gynecology, Tohoku University, Miyagi, Japan.

PMID: 30207096
PMCID: PMC6189428
DOI: 10.3802/jgo.2018.29.e88

No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

**Fig. 1. Temporal trends for HR change per CA-125 cutoff.**
Arrow mark indicates the reflection point of CA-125 levels on HR trends. CA-125 level between 5–125 IU/L: APC=0.09; 95% CI=0.05–0.14; p<0.001. CA-125 between 125–300 IU/L: APC=0.21; 95% CI=0.18–0.24; p<0.001. CA-125, cancer antigen 125; HR, hazard ratio; APC, annual percent change; and CI, confidence interval; PFS, progression-free survival.

**Fig. 2. PFS based on CA-125 cutoff.**
Log-rank test for p value. Pretreatment CA-125 levels were classified as: normal (<30 IU/L), abnormal (30–124 IU/L), and markedly high-risk (≥125 IU/L). PFS, progression-free survival; CA-125, cancer antigen 125.

See this image and copyright information in PMC

Comment on

Trends of uterine carcinosarcoma in the United States.
Matsuo K, Ross MS, Machida H, Blake EA, Roman LD. Matsuo K, et al. J Gynecol Oncol. 2018 Mar;29(2):e22. doi: 10.3802/jgo.2018.29.e22. Epub 2018 Jan 5. J Gynecol Oncol. 2018. PMID: 29400015 Free PMC article.

References

1. Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137:581–588. - PubMed
1. Matsuo K, Ross MS, Machida H, Blake EA, Roman LD. Trends of uterine carcinosarcoma in the United States. J Gynecol Oncol. 2018;29:e22. - PMC - PubMed
1. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017;31:411–423. - PMC - PubMed
1. Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, et al. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016;27:1257–1266. - PubMed
1. Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017;145:78–87. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

Gynecologic Cancer Research/International

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Affiliations

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous